Literature DB >> 23946288

Relaxin protects against renal ischemia-reperfusion injury.

Takuya Yoshida1, Hiromichi Kumagai, Tetsuya Kohsaka, Naoki Ikegaya.   

Abstract

Relaxin, a pregnancy hormone, has antiapoptotic and anti-inflammatory properties. The aim of this study was to determine the effects of relaxin on ischemia-reperfusion (IR)-induced acute kidney injury. Male rats underwent unilateral nephrectomy and contralateral renal IR (45 min of renal pedicle clamping). Rats were divided into three groups: 1) sham group, 2) IR group, and 3) IR-RLX group (rats treated with relaxin before ischemia). In this group, relaxin was infused at 500 ng/h via subcutaneous osmotic minipump for 24 h beginning 2 h before renal ischemia. At 24 h after reperfusion, renal function was assessed and kidneys were removed for analysis. There was no significant difference in blood pressure among the three groups. IR increased plasma levels of creatinine and urea nitrogen, and relaxin provided protection against the increases in these two parameters. Relaxin significantly decreased plasma TNF-α levels and renal TNF receptor 1 mRNA expression, compared with the IR group. Semiquantitative assessment of the histological lesions showed marked structural damage in IR rats compared with the IR-RLX rats. RLX significantly reduced apoptotic cell counts compared with the IR group. Overexpression of caspase-3 observed in the IR kidneys was reduced in the IR-RLX group. The results demonstrated that relaxin provided protection against IR-induced renal injury by reducing apoptosis and inflammation.

Entities:  

Keywords:  apoptosis; caspase-3; relaxin

Mesh:

Substances:

Year:  2013        PMID: 23946288     DOI: 10.1152/ajprenal.00654.2012

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  18 in total

Review 1.  Renoprotective approaches and strategies in acute kidney injury.

Authors:  Yuan Yang; Meifang Song; Yu Liu; Hong Liu; Lin Sun; Youming Peng; Fuyou Liu; Manjeri A Venkatachalam; Zheng Dong
Journal:  Pharmacol Ther       Date:  2016-04-22       Impact factor: 12.310

Review 2.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

4.  Shock wave induces biological renal damage by activating excessive inflammatory responses in rat model.

Authors:  Xiang Li; Qingzhi Long; Xinfa Cheng; Dalin He
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

5.  Inhibition of ubiquitin-activating enzyme protects against organ injury after intestinal ischemia-reperfusion.

Authors:  Shingo Matsuo; Andrew Chaung; Deanna Liou; Ping Wang; Weng-Lang Yang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-05-17       Impact factor: 4.052

Review 6.  Anti-fibrotic actions of relaxin.

Authors:  C S Samuel; S G Royce; T D Hewitson; K M Denton; T E Cooney; R G Bennett
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

7.  Relaxin does not improve Angiotensin II-induced target-organ damage.

Authors:  Nadine Haase; Julianna Rugor; Lukasz Przybyl; Fatimunnisa Qadri; Dominik N Müller; Ralf Dechend
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

Review 8.  Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.

Authors:  Javier Díez; Luis M Ruilope
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2015-11-26

9.  Anti-apoptotic and Matrix Remodeling Actions of a Small Molecule Agonist of the Human Relaxin Receptor, ML290 in Mice With Unilateral Ureteral Obstruction.

Authors:  Hooi Hooi Ng; Mariluz Soula; Bryan Rivas; Kenneth J Wilson; Juan J Marugan; Alexander I Agoulnik
Journal:  Front Physiol       Date:  2021-07-07       Impact factor: 4.566

10.  The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate.

Authors:  Chao Wang; Barbara K Kemp-Harper; Martina Kocan; Sheng Yu Ang; Tim D Hewitson; Chrishan S Samuel
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.